The results of the subgroup analysis indicated that both studies showed a potential benefit among patients with advanced disease (pT3‐4 or pN+), urinary bladder tumor, and baseline PD‐L1+ disease. This evidence concerns the gene CD274 and urinary bladder neoplasm.